

3 July 2025 EMA/119654/2025

Agenda – 14th Industry stakeholder platform on research and development support 3 July 2025, 12:30 - 17:30 (room 2A and TEAMS)

Co-chairs: Michael Berntgen and Iordanis Gravanis

Item	Agenda	Time
1.	 Welcome / Introductions Overview of the agenda Review of status of follow-up actions from the last platform meeting EMA: Michael Berntgen 	10 min
2.	A. Update from EMA on recent developments • Latest figures on volume and capacity • Application of latest guidance update, including scientific advice for paediatric developments • Experience with SAWP-CTCG pilots for providing scientific advice • Use of discussion meetings to enable scientific dialogue EMA: Iordanis Gravanis B. Developers' proposals to enable a more agile offering of scientific advice • Summary of outcome from a recent roundtable dialogue • Proposals to translate ideas into concrete activities Industry: Alexa Hunter (EFPIA/EuropaBio), Laura Oliveira (EFPIA/EuropaBio) C. Developers' proposals to enhance the SAWP-CTCG pilots • Experience with the pilots to-date • Reflections on strengthening the use of the new interface	60 min
	Industry: Laura Oliveira (EFPIA/EuropaBio)	



3.	Horizon scanning activities by different stakeholders	30 min
Э.	Methodologies employed by developers	
	Recent EMA activities on horizon scanning	
	EMA: Valentina Cordò, Enrico Tognana, Falk Ehmann Industry: Esteban Herrero-Martinez (EFPIA/EuropaBio), Seán Byrne (EUCOPE)	
4.	Experience with the new features of the PRIME scheme	45 min
	 Report from the pilot with feedback from developers of PRIME products focusing on expedited scientific advice, development tracker, and submission readiness meetings Additional insights through an industry survey on perceptions and expectations from PRIME Learnings from these surveys and further refinement of this development support offering for unmet medical need products 	
	EMA: Kevin Cunningham Industry: Nadege Le Roux (EFPIA)	
5.	Piloting of the product development coordinator for PRIME products	20 min
	 Introduction to the concept of the product development coordinator Discussion on expectations and metrics for measuring of value and impact 	
	EMA: Michael Berntgen, Iordanis Gravanis	
Coffee	e break	15 min
Coffee	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE)	15 min
	Focus group to explore opportunities for the use of Real World Data	
	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE)	
	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec	
6.	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec Industry: Almath Spooner (EFPIA), Marieke Schoonen (EUCOPE) Moving the stepwise Paediatric Investigation Plan (sPIP) concept from	15 min
6.	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec Industry: Almath Spooner (EFPIA), Marieke Schoonen (EUCOPE) Moving the stepwise Paediatric Investigation Plan (sPIP) concept from pilot to regular operations	15 min
6.	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec Industry: Almath Spooner (EFPIA), Marieke Schoonen (EUCOPE) Moving the stepwise Paediatric Investigation Plan (sPIP) concept from pilot to regular operations A. Update from EMA on recent developments • Final report from the "sPIP pilot" • Progress with the preparation of a joint publication on the experience • Monitoring and performance indicators to follow-up on sPIP	15 min
6.	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec Industry: Almath Spooner (EFPIA), Marieke Schoonen (EUCOPE) Moving the stepwise Paediatric Investigation Plan (sPIP) concept from pilot to regular operations A. Update from EMA on recent developments • Final report from the "sPIP pilot" • Progress with the preparation of a joint publication on the experience • Monitoring and performance indicators to follow-up on sPIP developments EMA: Chrissi Pallidis	15 min
7.	Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE) • Update on activities and next steps EMA: Andrej Segec Industry: Almath Spooner (EFPIA), Marieke Schoonen (EUCOPE) Moving the stepwise Paediatric Investigation Plan (sPIP) concept from pilot to regular operations A. Update from EMA on recent developments • Final report from the "sPIP pilot" • Progress with the preparation of a joint publication on the experience • Monitoring and performance indicators to follow-up on sPIP developments EMA: Chrissi Pallidis Industry: Gesine Bejeuhr (EFPIA), Marcello Milano (EUCOPE)	15 min 30 min

	Tognana (PTM), Tomas Balloti (SMEs BMs), Giampiero Lorenti (QIG)	
	B. Additional feedback on industry experience with Portfolio and Technology Meetings	
	Industry: Doerte Braumann (EFPIA)	
9.	Delivery of the action plan to strengthen qualification of novel methodologies	15 min
	Update on the activities under the action plan	
	EMA: Thorsten Vetter Industry: Cathelijn De Gram (EFPIA)	
10.	Establishment of potential alternatives to animal testing in line with the 3Rs principles	20 min
	New opportunities for voluntary data submission	
	EMA: Stefano Ponzano, Orla Moriarty	
11.	Summary of follow up items / Close of the meeting EMA: Michael Berntgen	10 min